News ImmuneRegen NewsImmuneRegen Responds to Canadian Defense Ministry With Possible Treatment for AnthraxMarch 16, 2005 08:30:00 AM ETFinal Protocols on Radilex™ Compound Submitted for Canada's 'Universal Protectants Proposal' SCOTTSDALE, Ariz., March 16 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that it has submitted its final response to an invitation to participate in the Canadian Defense Ministry's "Universal Protectants Proposal." The goal of this program is to find a "universal" treatment for chemical, biological, radiological, and nuclear (CBRN) threats, such as Anthrax or dirty bombs. The Proposal is under the auspices of the Ottawa and Suffield provencial branches of the Canadian Defense Ministry's R & D program, The CBRN Research and Technology Initiative (CRTI). "We believe Radilex™ to be one of the best universal protectant candidates available against CBRN attacks, since our methods of action do not simply neutralize the attacking agent, but actually increase immune system activity, thereby allowing the body's own immune system to attack and overcome the CBRN agent," commented Dr. Mark Witten, co-founder and Chief Scientific Officer of ImmuneRegen Biosciences, Inc. "We believe it is crucial in the war on terrorism that Radilex™ be utilized as a possible treatment for anthrax exposure in emergency events such as the recent detection of anthrax in the Pentagon mail facility on March 14." On March 11 ImmuneRegen submitted a formal proposal for inclusion in the Universal Protectants Proposal respective to the Company's compound Radilex(TM), currently in development for treating the negative and possibly deadly effects of: * Anthrax Recent testing of Radilex™ using Total Body Irradiation (TBI) showed a 100% survival rate among irradiated mice treated with Radilex™ Post Lethal Exposure (PLE). ImmuneRegen also recently responded to a Request for Information (RFI) from the U.S. Department of Health and Human Services (DHHS) regarding potential therapeutics for the treatment for Acute Radiation Syndrome (ARS). About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|